Back to top
more

Baxter International Inc. (BAX)

(Delayed Data from NYSE)

$82.19 USD

82.19
1,348,430

+0.73 (0.90%)

Updated Oct 22, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (155 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Baxter (BAX) to Report Q3 Earnings: What's in the Offing?

Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.

Baxter International (BAX) Earnings Expected to Grow: Should You Buy?

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings

Debanjana Dey headshot

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

Baxter's (BAX) Premix Norepinephrine Now Available in U.S.

Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.

    Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How

    Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.

    Hill-Rom (HRC) Agrees to Get Acquired by Baxter, Shares Jump

    The transaction is expected to close by early 2022 subject to the approval of Hill-Rom (HRC) shareholders and the fulfillment of customary closing conditions.

    Baxter International (BAX) Q2 Earnings Surpass Estimates

    Baxter (BAX) delivered earnings and revenue surprises of 8.11% and -0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Baxter (BAX) Q2 Earnings Surpass Estimates, Revenues Miss

    Baxter's (BAX) second-quarter results reflect robust performance across all its business units.

    Why the Earnings Surprise Streak Could Continue for Baxter (BAX)

    Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

    Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.

    Baxter (BAX) to Report Q2 Earnings: What's in the Cards?

    Baxter's (BAX) second-quarter results are likely to reflect growth in its Acute Therapies business.

    Baxter International (BAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Riya Anand headshot

    3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19

    Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.

    Walgreens (WBA), VillageMD State 2021 Primary Healthcare Goal

    With this Walgreens (WBA) and VillageMD are on track to achieve their January 2021 goal of opening at least 600 Village Medical primary care practices in more than 30 U.S. markets over the next four years.

    QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark

    QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.

    Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice

    Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.

    Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics

    Thermo Fisher's (TMO) new research collaboration is aimed to provide the metabolomics community with advanced, best practices and standard operating procedures.

    Here's Why You Should Retain AmerisourceBergen (ABC) Now

    AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment.

    IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?

    Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).

    Here's Why You Should Add STERIS (STE) to Your Portfolio

    Investors are optimistic about STERIS (STE) owing to strong segmental performance and bullish 2022 outlook.

      QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt

      With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.

      Surmodics (SRDX) Boosts Portfolio With Vetex Medical Buyout

      Surmodics' (SRDX) buyout of Vetex Medical adds second FDA 510 (k) cleared device to its thrombectomy platform.